Results 171 to 180 of about 39,708 (253)

Pregnancy‐related effect on elexacaftor, tezacaftor and ivacaftor pharmacokinetics in women with cystic fibrosis

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim The number of pregnancies among women with cystic fibrosis (wwCF) has steadily increased over the past decade. However, the pharmacokinetics (PK) of elexacaftor–tezacaftor–ivacaftor (ETI) during gestation remains uncharacterized, despite its widespread use in this population.
Paulette Magnas   +16 more
wiley   +1 more source

Seizure Burden before and after Lidocaine as Add-On Therapy in (Amplitude-Integrated) Electroencephalography-Confirmed Neonatal Seizures.

open access: yesNeonatology
Rondagh M   +7 more
europepmc   +1 more source

Incidence of Neonatal Seizures in China Based on Electroencephalogram Monitoring in Neonatal Neurocritical Care Units.

open access: yesJAMA Netw Open, 2023
Yan K   +31 more
europepmc   +1 more source

Codeine toxicity via breast Milk: Can this occur and implications for opiate therapy in children

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Codeine is commonly used in combination analgesic products. The use of codeine during breastfeeding can rarely be associated with serious adverse effects related to genetic polymorphisms affecting codeine's metabolism and disposition. Clinicians treating infants of breastfeeding mothers should be aware of this rare but potentially serious complication.
Michael Rieder
wiley   +1 more source

UGT1A1 genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Irinotecan, a topoisomerase I inhibitor, is available as both non‐pegylated and pegylated formulations. The non‐pegylated formulation is licensed for use in advanced colorectal cancer either in combination with other agents or as monotherapy.
Dharmisha Chauhan   +24 more
wiley   +1 more source

Relationship between continuous infusion meropenem PK/PD target attainment and C‐reactive protein dynamics in onco‐haematologic patients with febrile neutropenia

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Meropenem is a second‐line antimicrobial agent in the treatment of febrile neutropenia in onco‐haematological patients. A population pharmacokinetic/pharmacodynamic (PK/PD) analysis for assessing the relationship between meropenem exposure and C‐reactive protein (C‐RP) over time was conducted.
Chun Liu   +7 more
wiley   +1 more source

Impact of cumulative glucocorticoid exposure on vancomycin clearance in hospitalized children: A retrospective cohort study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Prior glucocorticoid exposure is associated with modestly increased vancomycin clearance in hospitalized children, partly mediated by renal function and inflammation and may contribute to subtherapeutic early drug exposure. Abstract Introduction Augmented renal clearance (ARC) can lead to subtherapeutic vancomycin exposure in children.
Kouki Tomari   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy